VOR and REGMY Related Headlines
Go Back- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Vor Bio reports positive telitacicept trial results in kidney disease
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
- Vor Bio to present phase 3 Sjögren's disease study data at medical meeting
- Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
- Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
VOR and REGMY Related Press Releases
Go Back- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
- Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
- Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
